Filing Details

Accession Number:
0000899243-22-037941
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-07 19:56:04
Reporting Period:
2022-12-05
Accepted Time:
2022-12-07 19:56:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1750019 Tcr2 Therapeutics Inc. TCRR () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1556064 E Garry Menzel C/O Tcr2 Therapeutics
100 Binney Street
Cambridge MA 02142
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-12-05 8,530 $1.37 204,120 No 4 S Direct
Common Stock Disposition 2022-12-06 14,886 $1.35 189,234 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 132,729 Indirect See Footnote
Common Stock 132,730 Indirect See Footnote
Common Stock 212,650 Direct
Footnotes
  1. Consists of 132,729 shares of common stock held by the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010, to the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Menzel Trust"). The reporting person is the trustee of the Menzel Trust, and as such the reporting person may be deemed to beneficially own such securities. The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust.
  2. Consists of 132,730 shares of common stock held by and the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Henshall Trust"). The reporting person's spouse is the trustee of the Henshall Trust, and as such the reporting person may be deemed to beneficially own such securities. The reporting person and members of his immediate family are the sole beneficiaries of the Henshall Trust.
  3. The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.
  4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.371 to $1.372. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.333 to $1.371. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request